Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)|cas:2094516-02-4|西域试剂

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)

产品编号：Bellancom-P99356| CAS NO：2094516-02-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99356	￥3500.00	杭州北京（现货）
Bellancom-P99356	￥9100.00	杭州北京（现货）
Bellancom-P99356	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)

产品介绍

Cinpanemab (BIIB054) 是一种人源单克隆抗体，可与 α-突触核蛋白 1-10 位残基结合。Cinpanemab 可用于研究帕金森病。

生物活性

Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.

体外研究

Cinpanemab 对聚合形式的 α-syn 具有高度选择性，对纤维状重组 α-syn 的表观亲和力至少比单体重组 α-syn 高 800 倍，并且对人 PD 脑组织有强烈的偏好。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain
Dosage:	30 mg/kg
Administration:	Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice
Result:	Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.

体内研究

Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain
Dosage:	30 mg/kg
Administration:	Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice
Result:	Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.